Ionis Inhaled Antisense Drug Shows Potential In CF
Promising In COPD And Asthma Too
The Phase I trial of IONIS-ENAC-2.5Rx for cystic fibrosis represents the first time an antisense medicine delivered directly to the lung has shown a significant reduction in ENaC messenger RNA levels.
